This case report illustrates the effectiveness of neoadjuvant imatinib for treating facial dermatofibrosarcoma protuberans, emphasizing molecular guidance.
Background: Dermatofibrosarcoma protuberans (DFSP) is a rare mesenchymal skin tumor characterized by slow growth, local aggressiveness, and a low metastatic potential. Facial involvement is uncommon, posing diagnostic and therapeutic challenges. Case Presentation: We report the case of a 38-year-old male presenting with a progressively enlarging mass on the right cheek. Imaging and biopsy confirmed DFSP, and molecular testing identified the COL1A1-PDGFB fusion. Given the lesion’s size, muscular infiltration, and potential functional and aesthetic morbidity, neoadjuvant imatinib (400 mg/day) was administered for three cycles, achieving a 40% volumetric reduction. This allowed a wide local excision with clear margins (R0) and local flap reconstruction, preserving facial function and aesthetics. At 12 months follow-up, the patient remained in complete remission without local recurrence or metastasis. Conclusion: This case illustrates the efficacy of neoadjuvant imatinib in locally advanced DFSP of the head and neck, facilitating conservative surgical management. Molecular confirmation of COL1A1-PDGFB fusion is essential to guide targeted therapy. Lifelong surveillance remains crucial due to the risk of late local recurrence.
No takes yet. Share an insight, caveat, or question.
Benkacem et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: